title: Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload.
abstract: We compared 48-hour urinary iron excretion after a twice-daily subcutaneous bolus injection of deferoxamine and after 12 hours of subcutaneous continuous infusion of the drug in 27 patients with iron overload (mean age, 55.7 years). In most patients, the iron overload was due to multiple transfusions administered during chemotherapy or as part of supportive care for a hematologic or oncologic disorder. One patient had sickle cell anemia and 1 had hereditary hemochromatosis and spherocytosis. Similar urinary iron excretion was observed with the 2 methods of administration; mean +/- SD values were 6935.3 +/- 3832.3 microg/48 hours with subcutaneous bolus injection and 6630.4 +/- 3606.9 microg/48 hours with subcutaneous continuous infusion (P =.3). Twenty-six patients (96.3%) chose to continue therapy with bolus injection. The long-term efficacy of bolus injection was evaluated by measuring the serum ferritin concentration at regular intervals for a follow-up time of 20.1 +/- 4.5 months. Ferritin concentration decreased to below 1000 microg/L in 73% of the patients and to below 500 microg/L in 42% and became normal in 26%. Best results were obtained in patients who were no longer receiving blood transfusions when chelation therapy was initiated. Three of 26 patients (11.5%) had mild, transient side effects after bolus injection. Larger prospective, randomized studies must be conducted before deferoxamine bolus injection can be routinely recommended for patients with iron overload. (Blood. 2000;95:2776-2779)
authors.affiliation: Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Franchini
authors.forename: G
authors.initials: G
authors.lastname: Gandini
authors.forename: M
authors.initials: M
authors.lastname: de Gironcoli
authors.forename: A
authors.initials: A
authors.lastname: Vassanelli
authors.forename: C
authors.initials: C
authors.lastname: Borgna-Pignatti
authors.forename: G
authors.initials: G
authors.lastname: Aprili
mesh_terms: D000328:Adult; D000368:Aged; D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D007501:Iron / Q000652:urine; D019190:Iron Overload / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012449:Safety; D013997:Time Factors; D065227:Transfusion Reaction
chemical_list: D002614:Chelating Agents; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine